ReviewPharmaceuticals (Basel, Switzerland)2023
Heavy Metal-Based Nanoparticles as High-Performance X-ray Computed Tomography Contrast Agents.
Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Contrast Agents for Enhanced Bioimaging: A Comprehensive Review.Chembiochem : a European journal of chemical biology · 2026Review
- Potential of Silver Nanoparticles in Imaging Diagnostics and Image-Guided Applications: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Understanding and Exploiting Biological Mechanisms of Radiosensitization Using High Atomic Mass Nanomaterials.Nanomaterials (Basel, Switzerland) · 2026Review
- Novel High-Atomic-Number Element and Nanoparticle-Based CT Contrast Agents: Advanced Design Strategies and Clinical Translational Barriers.International journal of nanomedicine · 2026Review
- Advances in Versatile Copper Sulfide-Based Nanoplatforms: From Synthesis and Properties to Multifaceted Biomedical Applications.International journal of nanomedicine · 2026Review
- Targetable Biomimetic NIR-II Theranostic Nanoplatform for Highly Efficient Multimodal Imaging-Guided Photothermal Therapy of Cervical Cancer.International journal of nanomedicine · 2026Article
- Progress in the Development of Metal-Organic Frameworks (MOFs) for Medical Imaging of Tumors: Prospects and Challenges.International journal of nanomedicine · 2026Review
- Human serum albumin-based KBiFJournal of nanobiotechnology · 2025Article
- Magnetic Resonance Imaging and X-Ray Imaging Properties of Ultrasmall Lanthanide Oxide (Ln = Eu, Gd, and Tb) Nanoparticles Synthesized via Thermal Decomposition.Molecules (Basel, Switzerland) · 2025Article
- Novel impact of metal ion-induced cell death on diabetic cardiomyopathy pathogenesis and therapy.Apoptosis : an international journal on programmed cell death · 2025Review
- Emerging nanoparticle-based x-ray imaging contrast agents for breast cancer screening.Nanomedicine (London, England) · 2025Review
- Multienergy cardiovascular CT imaging: current state and future.The British journal of radiology · 2025Review
- Nanomedicine and clinical diagnostics part I: applications in conventional imaging (MRI, X-ray/CT, and ultrasound).Nanomedicine (London, England) · 2025Review
- A comprehensive review on nanoparticle-based photo acoustic: current application and future prospective.Discover nano · 2024Review
- Targeted K-Edge Nanoprobes From Praseodymium and Hafnium for Ratiometric Tracking of Dual Biomarkers using Spectral Photon Counting CT.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Advanced soft tissue visualization in conjunction with bone structures using contrast-enhanced micro-CT.Journal of medical imaging (Bellingham, Wash.) · 2024Article
- Nanoparticle Contrast Agents for Photon-Counting Computed Tomography: Recent Developments and Future Opportunities.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
X-ray computed tomography (CT) contrast agents offer extremely valuable tools and techniques in diagnostics via contrast enhancements. Heavy metal-based nanoparticles (NPs) can provide high contrast in CT images due to the high density of heavy metal atoms with high X-ray attenuation coefficients that exceed that of iodine (I), which is currently used in hydrophilic organic CT contrast agents. Nontoxicity and colloidal stability are vital characteristics in designing heavy metal-based NPs as CT contrast agents. In addition, a small particle size is desirable for in vivo renal excretion. In vitro phantom imaging studies have been performed to obtain X-ray attenuation efficiency, which is a critical parameter for CT contrast agents, and the imaging performance of CT contrast agents has been demonstrated via in vivo experiments. In this review, we focus on the in vitro and in vivo studies of various heavy metal-based NPs in pure metallic or chemical forms, including Au, Pt, Pd, Ag, Ce, Gd, Dy, Ho, Yb, Ta, W, and Bi, and provide an outlook on their use as high-performance CT contrast agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.